Jeffrey Alderman

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents
    Jeffrey Alderman
    Pfizer Inc, New York, New York 10017, USA
    J Child Adolesc Psychopharmacol 16:117-29. 2006
  2. ncbi request reprint Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers
    Jeffrey Alderman
    Pfizer Inc, New York, NY 10017, USA
    Clin Ther 27:1050-63. 2005
  3. ncbi request reprint Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review
    Ninan T Mathew
    Houston Headache Clinic, Houston, TX 77004, USA
    Headache 43:962-74. 2003

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents
    Jeffrey Alderman
    Pfizer Inc, New York, New York 10017, USA
    J Child Adolesc Psychopharmacol 16:117-29. 2006
    ..The aim of this study was to evaluate the long-term pharmacokinetics, safety, and efficacy of sertraline in children and adolescents with obsessive-compulsive disorder (OCD) or major depressive disorder (MDD)...
  2. ncbi request reprint Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers
    Jeffrey Alderman
    Pfizer Inc, New York, NY 10017, USA
    Clin Ther 27:1050-63. 2005
    ....
  3. ncbi request reprint Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review
    Ninan T Mathew
    Houston Headache Clinic, Houston, TX 77004, USA
    Headache 43:962-74. 2003
    ..Background.-Eletriptan is a potent and selective 5-HT1B/1D agonist that has demonstrated significant efficacy in the acute treatment of migraine in doses of 20 mg, 40 mg, and 80 mg...